Curis mit frischem Patent und
Seite 1 von 1 Neuester Beitrag: 27.01.04 15:11 | ||||
| Eröffnet am: | 09.04.03 18:12 | von: Eskimato | Anzahl Beiträge: | 25 |
| Neuester Beitrag: | 27.01.04 15:11 | von: Dr.UdoBroem. | Leser gesamt: | 5.323 |
| Forum: | Börse | Leser heute: | 1 | |
| Bewertet mit: |  | |||
Gruss E.
CURIS Issued U.S. Patent Covering Cancer Drug Candidates
WEDNESDAY, APRIL 09, 2003 8:13 AM
- BusinessWire
CAMBRIDGE, Mass., Apr 9, 2003 (BUSINESS WIRE) -- CURIS, Inc. (CRIS) - The U.S. Patent and Trademark Office yesterday issued a patent covering a class of compounds that are being developed by CURIS for use as cancer treatments.
These compounds have been specifically designed as inhibitors of a biological signaling pathway controlled by a protein called Hedgehog.
"Abnormal activation of the Hedgehog signaling pathway has been implicated in several cancers, including basal cell carcinoma, medulloblastoma, small cell lung cancer, and others," stated Dr. Lee Rubin, CURIS' Chief Scientific Officer. "We believe that inhibition of the Hedgehog pathway may prove to be a novel and significant addition to the therapeutic options available for the treatment of certain cancers."
U.S. Patent 6,545,005, entitled "Mediators of the Hedgehog Signaling Pathway, Compositions and Uses Related Thereto," encompasses one of several classes of small molecule antagonists of the Hedgehog pathway that are being developed by CURIS as cancer treatments. The Company is also evaluating antibody therapy as another means of blocking the Hedgehog signaling pathway.
"This patent is another in a series of composition and method patents that further provide broad intellectual property coverage to CURIS' Hedgehog pathway inhibition technologies," said Daniel Passeri, CURIS' President and Chief Executive Officer. "The potential utility of this approach for cancer treatment was well illustrated with a recent publication in The Proceedings of the National Academy of Sciences. In that report, one of CURIS' Hedgehog pathway antagonists, CUR-61414, demonstrated success in selectively killing cancer cells in two different models of basal cell carcinoma, a skin cancer with more than one million new cases diagnosed annually in the U.S."
About CURIS, Inc.
CURIS, Inc. is a therapeutic drug development company. The Company's technology focus is on regulatory pathways that control repair and regeneration. CURIS' product development involves the use of proteins or small molecules to modulate these pathways. CURIS has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of kidney disease, neurological disorders, cancer, and alopecia (hair loss). For more information, please visit the CURIS web site at www.curis.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning Curis' or management's intentions, plans, expectations or predictions of future events are forward-looking statements. Such statements may contain the words "believes", "expects", "anticipates", "plans", "estimates" or similar expressions. Forward looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from those indicated by such forward-looking statements. Actual results can be affected by, among other things, uncertainties relating to product development, clinical trials, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, changes in or an inability to execute Curis' realigned business strategy and other risk factors identified in Curis' most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission. Curis disclaims any intention or obligation to update any of the forward-looking statements after the date of this press release.
CURIS, Inc., Cambridge
Christopher U. Missling, Ph.D., 617/503-6587
or Marc F. Charette, Ph.D., 617/503-6629
(c) 2003 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.
PMTI guckst Du auch, gelle. So als Tageszock hab ich mir nen paar MDR zur Eröffnung gekauft, hatte meine WL als überverkauft rausgespuckt. Schmeisse alle wieder für 2,35, wünsche mir aber nen kleinen Push bis 2,90, das wars dann schon.
Gruss E.
Source: Palomar Medical Technologies Inc
Palomar Q-YAG 5 Laser System Receives Clearance From the FDA for Skin Resurfacing
Wednesday April 9, 10:00 am ET
BURLINGTON, Mass., April 9 /PRNewswire-FirstCall/ -- Palomar Medical Technologies Inc (Nasdaq: PMTI - News) announced that it has received clearance from the FDA for skin resurfacing for its Palomar Q-YAG 59(TM) Nd: YAG Laser System. Laser skin resurfacing is a skin rejuvenation technique in which light energy is used to remove a superficial layer of the skin and stimulate
collagen production in the deeper layers of the skin for an improvement in the overall appearance of the skin. The Palomar Q-YAG 5 System includes a dual, blendable wavelength beam of 1064nm and 532nm. As the beam from the Palomar Q-YAG 5 System interacts with sun-damaged skin, it gently removes
the outer layer of the skin. Fine lines around the eyes and mouth are smoothed.
Deep creases and frown lines are softened and the appearance of acne scars is improved. Once the skin's outer layer is removed, the new skin beneath is softer and smoother with a more youthful appearance.
Tiffani Hamilton M.D. of the Atlanta Dermatology, Vein, and Research Center commented, "The Palomar Q-YAG 5 laser system is an important addition to our program. The skin resurfacing provided by this system has become an integral part of our comprehensive program to rejuvenate skin by smoothing out wrinkles and providing improved skin tone and texture to our clients."
Gruss E.
Eine der besseren Smallcapseiten - die haben viele interessante Aktien unter Beobachtung.
Sharper Image Reports a 37 Percent Increase in March Sales
Sharper Image March Same-Store Sales Rose 20%
Gruss E.
Curis to Present at Techvest European Healthcare Conference
CAMBRIDGE, Mass., May 14, 2003 (BUSINESS WIRE) -- Curis, Inc. (NASDAQ: CRIS)
announced today that Dr. Christopher U. Missling, CURIS' Chief Financial
Officer, will speak at the upcoming Techvest annual European healthcare
conference entitled "Opportunities in Global Biotech".
The conference will be held in Amsterdam, The Netherlands, on May 19-20.
The Techvest conference in Europe is held annually to promote continued contact
between biotechnology companies and venture capitalists and institutional
investors and to provide a platform to introduce new biotechnology companies to
the investment community. Dr. Missling will provide an update on Curis'
therapeutic product development programs and its plans for partnering with
pharmaceutical companies.
About Curis, Inc.
Curis, Inc. is a therapeutic drug development company. The Company's technology
focus is on regulatory pathways that control repair and regeneration. Curis'
product development involves the use of proteins or small molecules to modulate
these pathways. Curis has successfully used this technology and product
development approach to produce several promising drug product candidates in the
fields of kidney disease, neurological disorders, cancer, and alopecia (hair
loss). For more information, please visit the Curis web site at www.Curis.com.
This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Statements concerning Curis'
or management's intentions, plans, expectations or predictions of future events
are forward-looking statements. Such statements may contain the words
"believes", "expects", "anticipates", "plans", "estimates" or similar
expressions. Forward looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results to be
materially different from those indicated by such forward-looking statements.
Actual results can be affected by, among other things, uncertainties relating to
product development, clinical trials, regulatory actions or delays, the ability
to obtain or maintain patent or other proprietary intellectual property
protection, changes in or an inability to execute Curis' realigned business
strategy and other risk factors identified in Curis' most recent Annual Report
on Form 10-K and subsequent reports filed with the Securities and Exchange
Commission. Curis disclaims any intention or obligation to update any of the
forward-looking statements after the date of this press release.
SOURCE: Curis, Inc.
Curis and Project A.L.S. Launch Collaboration to Evaluate New Therapeutic Approach for Lou Gehrig's Disease
THURSDAY, JUNE 05, 2003 12:39 PM
- BusinessWire
CAMBRIDGE, Mass., Jun 5, 2003 (BUSINESS WIRE) -- Curis, Inc. (CRIS) and Project A.L.S. have formed a collaboration to evaluate a new therapeutic approach for the treatment of Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's Disease.
ALS is a fatal neuromuscular disease in which the motor nerve cells in the body progressively die. There is currently no cure or treatment. Project A.L.S. is a nonprofit organization that provides funds to prominent medical research laboratories to investigate possible treatments and cures for this always-fatal disease.
The focal point of the collaboration is a biological pathway controlled by a signaling protein known as Hedgehog. Hedgehog is a key regulator in the body that, among other properties, promotes the development of motor nerve cells from progenitor or stem cells. Many of the scientific studies funded by Project A.L.S. involve attempts to use progenitor or stem cells as a replenishment source for new motor nerve cells. It is hoped that Curis' Hedgehog compounds or the combination of Curis' Hedgehog compounds with progenitor or stem cells will prove efficacious as a potential treatment for ALS.
"True collaboration is necessary to achieve an eventual understanding of ALS," said Jenifer Estess, Chief Executive Officer of Project A.L.S., who also has the disease. "We are thrilled to begin a collaboration with Curis and our research investigators. Anytime we can test the potential of promising new drug candidates, we increase the likelihood of finding an effective treatment."
"The recent study (funded by Project A.L.S. and published by Dr. Thomas Jessell and his associates of Columbia University in collaboration with Curis scientists) demonstrating that stem cells can be converted into motor nerve cells by the addition of Hedgehog, is very encouraging," said Dr. Lee Rubin, Curis' Chief Scientific Officer. "While a great deal more research needs to be done, the collaboration with Project A.L.S. and its investigators will provide significant insight into the therapeutic potential of the Hedgehog pathway as a treatment option for ALS."
"We are very pleased with the opportunity to collaborate with Project A.L.S.," said Daniel Passeri, Curis' President and Chief Executive Officer. "Collaborations such as these not only offer the prospect of finding potential treatments for this terrible disease, but they also increase the likelihood of a partnership with a large pharmaceutical company that could bring even more resources toward the goal of finding a cure for ALS."
About Curis, Inc.
Grüße
Pavian
Curis vorgestellt wurde, damals ist dieses neue Unternehmen aus einer Fusion entstanden.
Wichtig ist, wann man wieder einsteigen muss, und diesen Zeitpunkt hab ich hier geschickt vorgestellt. Wenn Du zu 1,30 seit Beginn meines Postings nachgekauft hättest...
Ich hab auch noch die "Welt" rumfliegen, als die den Webweltindex geführt hatten mit Akamai, Verticalnet, Satyam Infoway, Vignettte, und, und, und..
Wenn man dann aber etwa erkennt wie AKAM wieder anläuft, kann man bald auch wieder von ATH sprechen, ich meine dann in der Regel das 52 Wochen High.
Oder meine EZEN, die ich zu 0,42 gekauft habe, befinden sich zur Zeit auf 52 Wochen Hoch.
Na für Ezenia wurde in Bubble-zeiten 40 Dollar bezahlt.
Muss jetzt schlafen. Ach Pavian, ich bin fasziniert von Deinen MTLGs, seit 10 im Depot, jetzt bei 37 Dollar. Vielleicht läuft MTLG wie HOV?, der 5-Jahres-Chart:
Gruss E.
| CRIS 5.95 +0.76 |
| Tue Jan 13, 2004 | |
| • | Integrated Silicon, Raindance, and more |
| • | Curis shares surge on Wyeth pact, pacing sector |
| • | Biotech stocks mixed, Curis jumps |
| Mon Jan 12, 2004 | |
| • | Curis shares jump 26% on deal with Wyeth Pharma |
| • | Curis Announces Strategic Partnership with Wyeth Pharmaceuticals to Develop Therapeutics for Neurological Disorders |
| • | Curis, Wyeth In Product Development Pact |
| • | Curis Licensee Amylin Pharmaceuticals Files IND Application with the FDA for a PYY Compound in the Treatment of Obesity |
| Fri Jan 09, 2004 | |
| • | Curis Executive Officers Adopt Rule 10b5-1 Securities Trading Plans |
| Wed Dec 24, 2003 | |
| • | Curis falls on plans to sell $40M in securities |
könnte man wieder Einsteigen -->außergewöhnliches volumen
zur zeit + 70,50$ war das Zwischenhoch Mitte Juni ??
Grüsse Buju
hey ya, Buju
Gruss E.
gestern und heute extrem vernachlässigt!
Hatte auf Risiko versucht, wollte ein paar %
aufholen...ging nach hinten los...werde heute
abend mal nachschauen...gutes Schaffen!
Gruss Buju
hey ya, Buju
patzi
Truth is stranger than fiction, because fiction has to make sense